Publicaciones en colaboración con investigadores/as de GlaxoSmithKline (United Kingdom) (3)

2024

  1. Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma

    Cancer

2023

  1. A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 4, pp. 711-722

2021

  1. Minimal residual disease in Myeloma: Application for clinical care and new drug registration

    Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212